Sfoglia per AUTORE
HARRISON C
Collezione AOU Novara

  

Items : 9

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. in Nature medicine / Nat Med. 2025 May;31(5):1531-1538. doi: 10.1038/s41591-025-03572-3. Epub 2025 Mar 10.
2025
AOU Novara

Rampal RK; Grosicki S; Chraniuk D; Abruzzese E; Bose P; Gerds AT; Vannucchi AM; Palandri F; Lee SE; Gupta V; Lucchesi A; Oh ST; Kuykendall AT; Patriarca A; Álvarez-Larrán A; Mesa R; Kiladjian JJ; Talpaz M; Scandura JM; Lavie D; Harris M; Kays SK; Li Q; Boxhammer R; Brown B; Jegg AM; Harrison CN; Mascarenhas J;

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Nov 10;41(32):4993-5004. doi: 10.1200/JCO.22.01972. Epub 2023 Mar 7.
2023
AOU Novara

Mascarenhas J; Kremyanskaya M; Patriarca A; Palandri F; Devos T; Passamonti F; Rampal RK; Mead AJ; Hobbs G; Scandura JM; Talpaz M; Granacher N; Somervaille TCP; Hoffman R; Wondergem MJ; Salama ME; Colak G; Cui J; Kiladjian JJ; Vannucchi AM; Verstovsek S; Curto-García N; Harrison C; Gupta V;

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. in Future oncology (London, England) / Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11.
2022
AOU Novara

Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J;

Breakthrough infections in MPN-COVID vaccinated patients. in Blood cancer journal / Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8.
2022
AOU Città della Salute di Torino
AOU Novara

Curto-Garcia N; Carbonell S; Cavalca F; Borsani O; Bucelli C; Betti S; Kulikowska de Na??cz A; Cattaneo D; Guenova M; Navas Elorza B; Cichocka E; Angona A; Kusec R; Xicoy Cirici B; Sagues Serrano M; Carli G; Lopez Abadia E; Sanchez AM; Hernandez-Boluda JC; Garcia-Gutierrez V; Quiroz Cervantes K; Griesshammer M; Heidel FH; Bolaños Calderón E; Kiladjian JJ; Koschmieder S; Magro Mazo E; Foncillas MA; Osorio S; et alii...

Second versus first wave of COVID-19 in patients with MPN. in Leukemia / Leukemia. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. Epub 2022 Jan 21.
2022
AOU Città della Salute di Torino
AOU Novara

Curto-Garcia N; Betti S; Benajiba L; Borsani O; Cavalca F; Masternak Kulikowska de Na??cz A; Cichocka E; Cattaneo D; Bucelli C; Koschmieder S; Lopez Abadia E; Angona A; Xicoy Cirici B; Navas Elorza B; Sagues Serrano M; Kusec R; Carreno-Tarragona G; Osorio S; Hernandez-Boluda JC; Ruggeri M; Magro Mazo E; Marin Sanchez A; Griessammer M; Garcia-Gutierrez V; Bolaños Calderón E; Patriarca A; Quiroz Cervantes K; Kiladjian JJ; Alvarez-Larran A; et alii...

Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. in American journal of hematology / Am J Hematol. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. Epub 2022 Sep 27.
2022
AOU Città della Salute di Torino
AOU Novara

Curto-Garcia N; Rambaldi A; Betti S; Bellini M; Borsani O; Cavalca F; Cichocka E; Cattaneo D; de Na??cz AK; Bucelli C; Koschmieder S; Navas Elorza B; Angona A; Xicoy Cirici B; Lopez Abadia E; Sagues Serrano M; Kusec R; Osorio S; Carreno-Tarragona G; Hernandez-Boluda JC; Magro Mazo E; Carli G; Garcia-Gutierrez V; Marin Sanchez A; Patriarca A; Quiroz Cervantes K; Griesshammer M; Bolaños Calderón E; Kiladjian JJ; et alii...

Long-term follow-up of recovered MPN patients with COVID-19. in Blood cancer journal / Blood Cancer J. 2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0.
2021
AOU Città della Salute di Torino
AOU Novara

Guglielmelli P; Benajiba L; Bellosillo B; Cavalca F; Curto-Garcia N; Garrote M; Bellini M; Daffini R; Sobas MA; Cattaneo D; Cuevas B; Koschmieder S; Ruggeri M; Xicoy Cirici B; Angona A; Lopez Abadia E; Hernandez-Boluda JC; De Stefano V; Lunghi F; Bonifacio M; Garcia-Gutierrez V; Magro Mazo E; Navas Elorza B; Patriarca A; Rumi E; Osorio S; Benevolo G; Fox ML; Sagues Serrano M; et alii...

2021
AOU Città della Salute di Torino
AOU Novara

Harrison C; Rambaldi A; Bellini M; Betti S; Bellosillo B; Benajiba L; Curto-Garcia N; Cavalca F; Daffini R; Cattaneo D; Garrote M; Guglielmelli P; Cirici BX; Cuevas B; Hernandez-Boluda JC; Abadia EL; Carli G; Koschmieder S; Mazo EM; Angona A; Lunghi F; Patriarca A; Elorza BN; Sobas MA; Serrano MS; Carreno-Tarragona G; Bonifacio M; Cervantes KSQ; Osorio S; et alii...

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. in Leukemia / Leukemia. 2021 Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. Epub 2021 Jan 7.
2021
AOU Città della Salute di Torino
AOU Novara

Bellosillo B; Benajiba L; Curto-Garcia N; Bellini M; Daffini R; Cavalca F; Cattaneo D; Garrote M; Guglielmelli P; Cirici BX; Abadia EL; Cuevas B; Koschmieder S; Hernandez-Boluda JC; Ruggeri M; Mazo EM; Angona A; Elorza BN; Lunghi F; Patriarca A; Sobas MA; Serrano MS; Carreno-Tarragona G; Bonifacio M; Cervantes KSQ; Papadopoulos P; Rumi E; Osorio S; Morcillo CM; et alii...